Skip to main content
BRVE
NASDAQ Life Sciences

Braveheart Posts $26.5M Q3 Loss, $503.5M Cash Funds Runway Into 2029

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.62
Mkt Cap
$1.767B
52W Low
$16.7
52W High
$32
52W Position info
17% above low
Off High info
39% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BRVE sits 17% above its 52-week low of $16.7.

Summary

Braveheart reported a $26.5 million net loss, or $0.51 per share, for Q3 2026, with R&D at $17.5 million and G&A at $12.6 million. Cash, cash equivalents and investments stood at $503.5 million as of September 30, which the company says funds operations into 2029 — a long runway for a clinical-stage biotech. The update follows the November 6 AHA presentation of 52-week open-label extension data for BHB-1893 in oHCM, where pVO2 improved 2.7 mL/kg/min and KCCQ-CSS 17.3 points, and 57% of patients stayed on the 40 mg twice-daily starting dose at Week 52. Development plans are laid out: LIONHEART-HCM Phase 3 is enrolling with an interim LVOT-gradient analysis expected in the second half of 2027, while TRUEHEART-HCM Phase 2b and NOBLEHEART-HCM Phase 3 are slated to start in the first half of 2027. Partner Hengrui has finished enrollment in its China Phase 3 (Study 301), with topline results expected in the first half of 2027.

At the time of this announcement, BRVE was trading at $19.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $16.70 to $32.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BRVE - Latest Insights

BRVE
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.50 info
Change: +$0.880 (+4%) info
Market Cap: $1.842B info
BRVE
Nov 06, 2026, 3:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.50 info
Change: +$2.20 (+12%) info
Market Cap: $1.842B info
BRVE
Nov 06, 2026, 3:15 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.50 info
Change: +$2.20 (+12%) info
Market Cap: $1.842B info
BRVE
Sep 08, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.41
Real-time Price: $20.50 info
Change: -$8.91 (-30%) info
Market Cap: $1.842B info
BRVE
Aug 14, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $27.03
Real-time Price: $20.50 info
Change: -$6.53 (-24%) info
Market Cap: $1.842B info